# AbbVie

US immunology powerhouse — Humira (world's top-selling biologic 2012–2023) and Skyrizi/Rinvoq driving next-generation antibody manufacturing scale-up.

Source: https://en.bioecon.ru/companies/abbvie/
Updated: 2026-06-19

- Country: United States
- Revenue: $56.3B
- Employees: ~50,000 emp

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $100 billion committed to U.S. R&D and manufacturing capital investments over a decade; $2.2 billion in U.S. manufacturing investments announced since August 2025 | https://news.abbvie.com/2026-02-23-AbbVie-to-Invest-380-Million-in-North-Chicago-to-Further-Expand-Active-Pharmaceutical-Ingredient-Manufacturing-in-the-United-States, https://www.abbvie.com/content/dam/abbvie-com2/pdfs/manufacture/abbvie-illinois-impact-fact-sheet.pdf, https://www.abbvie.com/manufacturing-investments.html, https://www.prnewswire.com/news-releases/abbvie-selects-north-carolina-for-new-1-4-billion-manufacturing-campus-302750567.html |
| Capacity | Expanding domestic biologics, API, and small volume parenteral (SVP) drug product manufacturing capacity through multiple new facility investments in Illinois, North Carolina, Massachusetts, and Arizona | https://news.abbvie.com/2026-02-23-AbbVie-to-Invest-380-Million-in-North-Chicago-to-Further-Expand-Active-Pharmaceutical-Ingredient-Manufacturing-in-the-United-States, https://www.abbvie.com/manufacturing-investments.html, https://www.prnewswire.com/news-releases/abbvie-selects-north-carolina-for-new-1-4-billion-manufacturing-campus-302750567.html |
| Certification | 100% of device-manufacturing sites are ISO 13485 certified; sites also pursue ISO 14001, ISO 45001, and ISO 50001 certifications | https://www.abbvie.com/content/dam/abbvie-com2/pdfs/2025-esg-disclosure-supplement.pdf |
| Regulatory approval | Multiple ongoing FDA and EMA approvals for products like Skyrizi, Rinvoq, Vraylar, Ubrelvy, Qulipta, and Vyalev; recent approvals include Parkinson's disease therapy and c-Met overexpressing NSCLC treatment | https://investors.abbvie.com/static-files/c3b8b9e2-9d03-4d72-ad4b-2ae4ac0dedfc, https://www.fiercepharma.com/pharma/abbvie-hitting-record-sales-high-skyrizi-gains-holds-its-own-growing-ibd-arena-despite-jj, https://www.syneticx.com/blog/abbvie.html |
| Production site | Manufacturing sites in the U.S. (including Illinois, North Carolina, Arizona, Massachusetts) and internationally (Germany, Ireland, Italy, France, Puerto Rico, Costa Rica, Singapore) | https://news.abbvie.com/2026-02-23-AbbVie-to-Invest-380-Million-in-North-Chicago-to-Further-Expand-Active-Pharmaceutical-Ingredient-Manufacturing-in-the-United-States, https://www.abbvie.com/manufacturing-investments.html, https://www.abbviecontractmfg.com/resources/pharma-manufacturing-plant-capability-matrix.html, https://www.pharmamanufacturing.com/all-articles/article/55286102/abbvie-plans-10b-investment-in-us-manufacturing-over-the-next-decade, https://www.prnewswire.com/news-releases/abbvie-selects-north-carolina-for-new-1-4-billion-manufacturing-campus-302750567.html |
| Headcount | Approximately 57,000 global employees; approximately 29,000 employees in the U.S., including 6,000+ at U.S. manufacturing campuses | https://investors.abbvie.com/static-files/c3b8b9e2-9d03-4d72-ad4b-2ae4ac0dedfc, https://news.abbvie.com/2026-02-23-AbbVie-to-Invest-380-Million-in-North-Chicago-to-Further-Expand-Active-Pharmaceutical-Ingredient-Manufacturing-in-the-United-States, https://www.abbvie.com/content/dam/abbvie-com2/pdfs/manufacture/abbvie-illinois-impact-fact-sheet.pdf, https://www.abbvie.com/manufacturing-investments.html, https://www.prnewswire.com/news-releases/abbvie-selects-north-carolina-for-new-1-4-billion-manufacturing-campus-302750567.html |
| Revenue | $61.1 billion in total sales in 2025; total revenue of $16.99 billion for Q2 2026 | https://pulse2.com/abbvie-skyrizi-and-rinvoq-generate-8-03-billion-as-humira-revenue-falls-36/, https://www.fiercepharma.com/pharma/abbvie-hitting-record-sales-high-skyrizi-gains-holds-its-own-growing-ibd-arena-despite-jj |

Independent sources: fiercepharma.com, pharmamanufacturing.com, prnewswire.com, pulse2.com, syneticx.com

## Technologies

- [Biologics](https://en.bioecon.ru/technology/biologics/)
- [Biosynthetic hyaluronic acid](https://en.bioecon.ru/technology/biosynthetic-hyaluronic-acid/)
- [Bispecific & multispecific antibodies](https://en.bioecon.ru/technology/bispecific-antibodies/)
- [Recombinant botulinum toxin (biosynthetic Botox)](https://en.bioecon.ru/technology/recombinant-botulinum-toxin/)